JDRF Statement on Eli Lilly Announcement of a New, Lower Cost Generic Insulin:

“Lowering the cost of insulin is a critical priority for JDRF and the diabetes community, and why we have urged public and private sector actions to lower list prices and out-of-pocket costs. Eli Lilly announcing a lower-priced, generic version of insulin is an important step forward to make insulin more affordable. People with type 1 diabetes cannot go without insulin, and we need drug companies, health plans, employers, and the government to do more until everyone who needs it has affordable access to this life-saving drug.”- Derek Rapp, JDRF President and CEO.